Literature DB >> 18044343

[Melatonin in the treatment of atherosclerosis].

Marlena Broncel1, Marzena Koziróg-Kołacińska, Julita Chojnowska-Jezierska.   

Abstract

Atherosclerosis is currently concerned as a chronic inflammatory process, which is response to an endothelial damage. Therapy of atherosclerosis should influence on various mechanisms. Substances which can prevent and treat this disorder are still being investigated. Melatonin exerts anti-inflammatory and antioxidative properties, which implies that it can be useful in the treatment of atherosclerosis. Melatonin neutralizes ROS (reactive oxygen species), increases antioxidative enzymes activities and glutathione levels, prevents electron leakage from mitochondrial respiratory chain, acts synergistically with vitamins C, E, and glutathione. Melatonin reduces levels of proinflammatory cytokines: IL-6, IL-12, TNF-alpha, IFN-gamma. In vivo studies and experiments on animals melatonin exerts beneficial effect on serum lipids, prevents LDL oxidation, decreases TBARS levels, increases total antioxidant capacity. However, some studies suggest that melatonin can exert atherogenic effects in animals. Clinical studies on patients who are in risk of atherosclerosis development are required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18044343

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  4 in total

1.  The effects of melatonin on liver functions in arsenic-induced liver damage.

Authors:  İlhan Bali; Bülent Bilir; Seyfi Emir; Filiz Turan; Ahsen Yılmaz; Tuba Gökkuş; Murat Aydın
Journal:  Ulus Cerrahi Derg       Date:  2016-10-27

2.  Melatonin alleviates myosin light chain kinase expression and activity via the mitogen-activated protein kinase pathway during atherosclerosis in rabbits.

Authors:  Xiaowen Cheng; Yufeng Wan; Yuanhong Xu; Qing Zhou; Yuan Wang; Huaqing Zhu
Journal:  Mol Med Rep       Date:  2014-10-23       Impact factor: 2.952

Review 3.  Melatonin as a potential inhibitory agent in head and neck cancer.

Authors:  Chia-Ming Yeh; Shih-Chi Su; Chiao-Wen Lin; Wei-En Yang; Ming-Hsien Chien; Russel J Reiter; Shun-Fa Yang
Journal:  Oncotarget       Date:  2017-08-09

Review 4.  Effects of melatonin on cardiovascular diseases: progress in the past year.

Authors:  Hang Sun; Aaron M Gusdon; Shen Qu
Journal:  Curr Opin Lipidol       Date:  2016-08       Impact factor: 4.776

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.